Cybin Inc. (CYBN): Net earnings per share for the last 12 months

Symbol and logo of brand cybin.com (CYBN)

Cybin Inc. relies on strategic fundraising and patent protection, yet regulatory barriers in the psychedelic sector create uncertainty. The 12-month earnings per share history visualizes the struggle between these factors, where the value of -3.90 expresses the metric level. Growth prospects are supported by the implementation of AI modules for neuroimaging analysis and the robotization of molecule screening.

CYBN (Cybin Corp) Net earnings per share for the last 12 months history from 07/04/2022 to 01/05/2026

Analytical breakdowns and data insights for company Cybin Inc (CYBN)

- current quotes and average value forecast:
Price Chart Cybin Corp|CYBN - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Cybin Inc.|CYBN - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Cybin|CYBN - Company Net Assets|Market Capitalization to Book Value Ratio cybin.com|CYBN - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity Cybin Inc.|CYBN - Long-Term Liabilities to Capital|Short-Term Debt to Capital Cybin Corp|CYBN - Company Total Debt|Debt to Book Value Cybin Inc.|CYBN - Long-Term Debt|Company Short-Term Debts Cybin|Quick Ratio cybin.com
- net income and valuation multiples indicators:
CYBN - Net Financial Result|Expected Profit Cybin Inc.|CYBN - Price to Earnings Multiple|Projected Price to Earnings Cybin Corp|CYBN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Cybin Inc.|CYBN - Operating income before deduction of amortization|Earnings per share for the last twelve months Cybin|CYBN - Earnings per share for the last 12 months|Quarterly EPS earnings growth cybin.com|CYBN - Net earnings per share growth this year|Expected earnings per share growth for next year Cybin Inc.
Initial company analysis:cybin.com - CYBN
Mass-produced product of Cybin Inc

Cybin Inc. is a clinical-stage developer with no commercial revenue, whose viability relies entirely on raising external capital. Negative operating cash flow dictates the calculation logic of the metric as the ratio of total net loss to the number of shares, which allows the annual net income per share to track the cash burn rate and the fundamental value of each security.

Main competitors

ALKS - Earnings per share for the last twelve months|Net earnings per share for the last four quarters avadel.com AVDL|ATAI (atai Life Sciences) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months GH Research plc (GHRS)|MNMD (MindMed Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months COMPASS Corp (CMPS)|Net earnings per share (EPS TTM) LBRX|DRUG (brightmindsbio.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Vanda Pharmaceuticals Inc. VNDA|Alto Neuroscience Inc (ANRO) - Net earnings per one share for the last twelve months|NRx Pharma - Net earnings per share (EPS TTM)|Cingulate Inc. (CING) - Net earnings per share for the last 12 months|SILO (Silo Pharma, Inc.) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months China Pharma Holdings, Inc. (CPHI)|CMND (Clearmind Medicine) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months PBM|Net earnings per share (EPS TTM) SPRC|Net earnings per share for the last four quarters Seelos Therapeutics Inc|Earnings per share for the last twelve months Virpax Pharmaceuticals, Inc. VRPX|KRTX: Earnings per share for the last 12 months